Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

Antisense and Isis Extend Pact

  • Antisense Therapeutics (ANP) and Isis Pharmaceuticals agreed to extend their drug discovery and development collaboration for two years. The original collaboration allows ANP to select, test, and assess new antisense compounds for a variety of diseases and potential commercial markets.

    Through this agreement and its extension, ANP intends to add new products its pipeline, which currently includes ATL1102 for multiple sclerosis and ATL1103 for growth and sight disorders. ATL1103 is a direct product of this active collaboration.

    ANP holds worldwide exclusive licenses to any drug that it ultimately decides to develop and commercialize.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »